Allergy Therapeutics Cash Flow Statement

Financials in millions GBP. Fiscal year is July - June.

Millions GBP. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	-40.13	-38.62	-43.07	-13.78	2.89
Depreciation & Amortization	3.94	3.9	3.79	3.74	3.84
Other Amortization	0.23	0.42	0.43	0.42	0.29
Loss (Gain) From Sale of Assets	0.05	-	-	0.01	-
Stock-Based Compensation	0.87	0.76	0.11	0.47	0.64
Other Operating Activities	10.27	1.71	1.84	1.02	-0.64
Change in Accounts Receivable	0.27	0.14	3.38	-4.25	2.14
Change in Inventory	-1.02	-1.24	-0.18	-0.57	-1.12
Change in Accounts Payable	-2.58	0.79	4.82	-1.07	0.55
Operating Cash Flow	-28.11	-32.14	-28.88	-14	8.59
Operating Cash Flow Growth	-	-	-	-	-31.20%
Capital Expenditures	-3.26	-3.4	-4.67	-3.06	-2.56
Sale of Property, Plant & Equipment	0.27	2.07	-	-	-
Sale (Purchase) of Intangibles	-0.16	-	-	-	-
Other Investing Activities	0.27	0.14	0.08	0.06	-0.08
Investing Cash Flow	-2.89	-1.2	-4.59	-3	-2.64
Long-Term Debt Issued	40.31	37.09	36	-	0.63
Long-Term Debt Repaid	-7.27	-4.52	-11.53	-2.27	-2.36
Net Debt Issued (Repaid)	33.05	32.57	24.47	-2.27	-1.74
Issuance of Common Stock	-	2.42	7	0	0
Other Financing Activities	-1.88	-3.56	-3.67	-0.54	-0.49
Financing Cash Flow	31.16	31.43	27.8	-2.81	-2.22
Foreign Exchange Rate Adjustments	-0.29	-0.02	0	0.05	-0.42
Net Cash Flow	-0.13	-1.93	-5.67	-19.76	3.31
Free Cash Flow	-31.37	-35.54	-33.55	-17.06	6.03
Free Cash Flow Growth	-	-	-	-	-41.03%
Free Cash Flow Margin	-57.00%	-64.38%	-56.30%	-23.44%	7.15%
Free Cash Flow Per Share	-0.01	-0.01	-0.05	-0.03	0.01
Cash Interest Paid	1.16	2.5	3.16	0.54	0.49
Cash Income Tax Paid	0.57	0.15	0.45	0.21	-0.04
Levered Free Cash Flow	-12.86	-24.11	-19.5	-11.48	5.55
Unlevered Free Cash Flow	-8.88	-21.75	-18.15	-11.14	5.79
Change in Working Capital	-3.33	-0.31	8.02	-5.89	1.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.